CY1111085T1 - Ετεροκυκλικες-υποκατεστημενες πιπεριδινες ως οrl-1 συνδετες - Google Patents

Ετεροκυκλικες-υποκατεστημενες πιπεριδινες ως οrl-1 συνδετες

Info

Publication number
CY1111085T1
CY1111085T1 CY20101101169T CY101101169T CY1111085T1 CY 1111085 T1 CY1111085 T1 CY 1111085T1 CY 20101101169 T CY20101101169 T CY 20101101169T CY 101101169 T CY101101169 T CY 101101169T CY 1111085 T1 CY1111085 T1 CY 1111085T1
Authority
CY
Cyprus
Prior art keywords
heterocyclic
substituted
orl
peppers
connectors
Prior art date
Application number
CY20101101169T
Other languages
English (en)
Inventor
Yoshiyasu Baba
Kevin C Brown
Richard R Goehring
Naoki Tsuno
Original Assignee
Purdue Pharma L.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma L.P. filed Critical Purdue Pharma L.P.
Publication of CY1111085T1 publication Critical patent/CY1111085T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η εφεύρεση σχετίζεται με Ετεροκυκλικές-Υποκατεστημένες Πιπεριδινικές Ενώσεις, συνθέσεις οι οποίες περιλαμβάνουν μια αποτελεσματική ποσότητα μιας Ετεροκυκλικής-Υποκατεστημένης Πιπεριδινικής Ένωσης και μεθόδους για αντιμετώπιση ή πρόληψη μιας πάθησης, όπως πόνου, οι οποίες περιλαμβάνουν τη χορήγηση σε ένα ζώο το οποίο την έχει ανάγκη μιας αποτελεσματικής ποσότητας μιας Ετεροκυκλικής-Υποκατεστημένης Πιπεριδινικής Ένωσης.
CY20101101169T 2007-01-16 2010-12-17 Ετεροκυκλικες-υποκατεστημενες πιπεριδινες ως οrl-1 συνδετες CY1111085T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88095507P 2007-01-16 2007-01-16
US93003507P 2007-05-11 2007-05-11
EP08727696A EP2076506B1 (en) 2007-01-16 2008-01-15 Heterocyclic-substituted piperidines as orl-1 ligands

Publications (1)

Publication Number Publication Date
CY1111085T1 true CY1111085T1 (el) 2015-06-11

Family

ID=39434287

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101169T CY1111085T1 (el) 2007-01-16 2010-12-17 Ετεροκυκλικες-υποκατεστημενες πιπεριδινες ως οrl-1 συνδετες

Country Status (23)

Country Link
US (2) US8110602B2 (el)
EP (3) EP2397477B1 (el)
JP (2) JP5462633B2 (el)
KR (2) KR101227072B1 (el)
CN (1) CN101595100B (el)
AT (1) ATE482206T1 (el)
AU (2) AU2008206317B2 (el)
CA (1) CA2675419C (el)
CY (1) CY1111085T1 (el)
DE (1) DE602008002690D1 (el)
DK (1) DK2076506T3 (el)
ES (1) ES2353448T3 (el)
HK (1) HK1152296A1 (el)
HR (1) HRP20100691T1 (el)
IL (1) IL199741A0 (el)
MX (1) MX2009007644A (el)
NZ (2) NZ601683A (el)
PL (1) PL2076506T3 (el)
PT (1) PT2076506E (el)
RS (1) RS51474B (el)
SI (1) SI2076506T1 (el)
WO (1) WO2008089201A2 (el)
ZA (1) ZA200903742B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2076506E (pt) 2007-01-16 2010-12-10 Purdue Pharma Lp Compostos de piperidina substituídos nos grupos heterocíclicos como ligandos orl-1
EP2433935A1 (en) * 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2537844A1 (en) 2008-07-21 2012-12-26 Purdue Pharma L.P. Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
US20110295013A1 (en) * 2009-02-03 2011-12-01 Hiroshi Iwamura Process for preparing 1-(4-piperidinyl)benzimidazolone derivatives
WO2011030537A1 (ja) 2009-09-08 2011-03-17 杏林製薬株式会社 ４－（５－メチルピリジン－２－イルアミノ）ピペリジン－１－カルボン酸誘導体の製造方法
EP2631229B1 (en) * 2010-07-29 2014-12-03 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
JP5872585B2 (ja) * 2010-12-22 2016-03-01 パーデュー、ファーマ、リミテッド、パートナーシップ リン置換キノキサリンタイプピペリジン化合物とその使用
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2797912B1 (en) 2011-12-01 2016-05-25 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
KR20230164601A (ko) * 2022-05-25 2023-12-04 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
WO2023229380A1 (ko) * 2022-05-25 2023-11-30 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
DK0556393T3 (da) 1990-11-06 2000-10-16 Yamanouchi Pharma Co Ltd Tilkondenseret pyrazinderivat
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9314977D0 (en) 1993-07-20 1993-09-01 Glaxo Spa Chemical compounds
US5739129A (en) 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
PE27497A1 (es) 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JPH10511374A (ja) 1994-12-23 1998-11-04 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペラジン誘導体、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
JP3845876B2 (ja) 1995-04-20 2006-11-15 アステラス製薬株式会社 ピラジン誘導体又はその塩を含有する安定な注射用組成物及びその製造方法
JPH11507670A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
ATE276242T1 (de) * 1997-05-30 2004-10-15 Banyu Pharma Co Ltd 2-oxoimidazol-derivate
US6030130A (en) * 1997-07-07 2000-02-29 George Paddock Ii, Inc. Body mounted camera support system
JP3342478B2 (ja) * 1998-01-19 2002-11-11 ファイザー製薬株式会社 Ｏｒｌ１−レセプターアゴニストとしての４−（２−ケト−１−ベンズイミダゾリニル）ピペリジン化合物
DE69943144D1 (de) 1998-03-31 2011-03-03 Kyowa Hakko Kirin Co Ltd Stickstoffenthaltende heterocyclische verbindungen
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
CA2347938A1 (en) 1998-10-20 2000-04-27 Takahiro Matsumoto 1,5-benzodiazepine compounds, their production and use
WO2001034571A1 (en) 1999-11-09 2001-05-17 Eli Lilly And Company β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
US7456198B2 (en) * 1999-12-06 2008-11-25 Purdue Pharma L.P. Benzimidazole compounds having nociceptin receptor affinity
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
AU2002257114A1 (en) 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
EP1598340B1 (en) * 2001-04-18 2009-03-04 Euro-Celtique S.A. 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
HUP0402510A3 (en) * 2001-04-18 2012-08-28 Euro Celtique Sa Nociceptin analogs and pharmaceutical compositions containing them
ATE403429T1 (de) 2001-04-18 2008-08-15 Euro Celtique Sa Spiropyrazol-verbindungen
AU2002338424B2 (en) * 2001-04-18 2005-04-21 Euro-Celtique S.A. Benzimidazolone compounds
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
US7001901B2 (en) 2002-08-27 2006-02-21 Bristol-Myers Squibb Company Tetrazolylpropionamides as inhibitors of Aβ protein production
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP2007520493A (ja) 2004-02-03 2007-07-26 ユーロ−セルティーク エス．エイ． シアノイミノベンゾイミダゾールの合成
EP1791838A2 (en) 2004-09-15 2007-06-06 Schering-Plough Ltd. Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols
PT2076506E (pt) 2007-01-16 2010-12-10 Purdue Pharma Lp Compostos de piperidina substituídos nos grupos heterocíclicos como ligandos orl-1

Also Published As

Publication number Publication date
AU2008206317B2 (en) 2012-02-02
EP2076506A2 (en) 2009-07-08
PT2076506E (pt) 2010-12-10
EP2280008A2 (en) 2011-02-02
CN101595100B (zh) 2014-06-11
DK2076506T3 (da) 2011-01-10
US8110602B2 (en) 2012-02-07
KR20090101314A (ko) 2009-09-24
KR20120051759A (ko) 2012-05-22
EP2076506B1 (en) 2010-09-22
US20100022519A1 (en) 2010-01-28
NZ578078A (en) 2011-11-25
ES2353448T3 (es) 2011-03-02
ZA200903742B (en) 2010-02-24
AU2011200692B2 (en) 2012-02-09
US20120108575A1 (en) 2012-05-03
WO2008089201A2 (en) 2008-07-24
WO2008089201A3 (en) 2008-12-18
JP2014040467A (ja) 2014-03-06
NZ601683A (en) 2012-11-30
ATE482206T1 (de) 2010-10-15
CN101595100A (zh) 2009-12-02
PL2076506T3 (pl) 2011-03-31
DE602008002690D1 (de) 2010-11-04
AU2008206317A1 (en) 2008-07-24
KR101370434B1 (ko) 2014-03-06
JP2010516687A (ja) 2010-05-20
HRP20100691T1 (hr) 2011-01-31
KR101227072B1 (ko) 2013-01-29
EP2397477A1 (en) 2011-12-21
CA2675419A1 (en) 2008-07-24
EP2397477B1 (en) 2014-03-05
EP2280008A3 (en) 2011-07-06
CA2675419C (en) 2013-11-12
MX2009007644A (es) 2009-07-27
RS51474B (en) 2011-04-30
US8637502B2 (en) 2014-01-28
AU2011200692A1 (en) 2011-03-10
EP2280008B1 (en) 2013-05-29
SI2076506T1 (sl) 2011-01-31
JP5462633B2 (ja) 2014-04-02
HK1152296A1 (en) 2012-02-24
IL199741A0 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
CY1111085T1 (el) Ετεροκυκλικες-υποκατεστημενες πιπεριδινες ως οrl-1 συνδετες
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MY148657A (en) Trpv1 antagonists and uses thereof
UA116211C2 (uk) Синергічні композиції для захисту сільськогосподарських культур та їх застосування
CY1116828T1 (el) Πεπτιδια για απευαισθητοποιηση απο αλλεργιογονα
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201290919A1 (ru) Индазольные соединения и их применение
WO2009129246A3 (en) Compositions and methods for preparing and using same
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TW200744586A (en) Therapeutic compounds
WO2009147205A3 (en) Synergistic fungicidal mixtures
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
EA201001230A1 (ru) Пестицидные смеси
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
WO2008112647A3 (en) Nitroxide radical as a treatment for neurodegeneration
EA201001234A1 (ru) Пестицидные смеси
WO2014102594A3 (en) Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014020405A8 (en) Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
WO2014102592A3 (en) Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
MA32573B1 (fr) Combinaisons insecticides
EA201291384A1 (ru) Терапевтические агенты 976
MX2011003306A (es) Ligandos nicotinicos de receptor de acetilcolina y los usos de los mismos.
UA97540C2 (ru) Замещенные хиноксалином пиперидиновые соединения и их применение